Skip to Main Content

Paper Details

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer.
Cancers (Basel)
4
2020
AR, CCG1423, CRPC, Castrate-resistant prostate cancer, Enzalutamide, LuCaP 35CR, PSA, Prostate Cancer, SRF, Serum Response Factor, androgen, androgen receptor, derived xenograft model, enzalutamide, patient, patients, prostate specific antigen, serum response factor, tubulin
Author NameAffiliation
Eva CoreyUniversity of Washington
Colm MorrisseyUniversity of Washington
William M GallagherUCD Conway Institute, University College Dublin
William M GallagherUniversity College Dublin
  • 1 - 4

Datasets

Release 1.2